Literature DB >> 7295739

Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor.

T Tamaki, N Aoki.   

Abstract

Two plasma proteins, alpha 2-plasmin inhibitor and plasma fibronectin, are cross-linked to fibrin by plasma transglutaminase (R-glutaminyl-peptide : amine gamma-glutamyl-yltransferase, EC 2.3.2.13, fibrin stabilizing factor) when blood coagulation takes place. The cross-linking reactions of these proteins were analyzed by polyacrylamide gel electrophoresis in sodium dodecyl sulfate (SDS) using these radioactively labeled proteins. Both proteins were cross-linked exclusively to the alpha-chain of fibrin, and each of these cross-linking reactions proceeded independently without being influenced by the other cross-linking reaction. The cross-linking of fibronectin to the alpha-chain proceeded steadily at a rate similar to that of the cross-linked polymerization of the alpha-chain. In contrast, the cross-linking reaction of alpha2-plasmin inhibitor to fibrin proceeded markedly faster than that of fibrin polymerization but did not proceed further after reaching a certain relatively low level of cross-linking. Most of the cross-linked alpha 2-plasmin inhibitor molecules at this stage of the fibrin cross-linking were in the form of complex with the alpha-chain monomer. The complex with the alpha-chain monomer was gradually transformed to a complex with the alpha-chain polymer as the cross-linking polymerization of the alpha chain proceeded. The rate of the transformation was the same as that for the disappearance of the alpha-chain monomer, indicating that whether the alpha-chain was cross-linked to alpha 2-plasmin inhibitor or not, the alpha-chain underwent cross-linking polymerization at the same rate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7295739     DOI: 10.1016/0005-2744(81)90016-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.

Authors:  A Undas; B Brzezinska-Kolarz; K Brummel-Ziedins; J Musial; A Szczeklik; K G Mann
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

2.  Cross-linking of fibronectin to collagenous proteins.

Authors:  D F Mosher
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

3.  The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking.

Authors:  Steven R Fraser; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

Review 4.  Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Authors:  Alisa S Wolberg; Yaqiu Sang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-02       Impact factor: 10.514

5.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

6.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

7.  Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.

Authors:  J Mimuro; S Kimura; N Aoki
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.

Authors:  M Matsuda; M Baba; K Morimoto; C Nakamikawa
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

9.  Morphometric characterization of fibrinogen's αC regions and their role in fibrin self-assembly and molecular organization.

Authors:  Anna D Protopopova; Rustem I Litvinov; Dennis K Galanakis; Chandrasekaran Nagaswami; Nikolay A Barinov; Alexander R Mukhitov; Dmitry V Klinov; John W Weisel
Journal:  Nanoscale       Date:  2017-09-21       Impact factor: 7.790

10.  Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots.

Authors:  C Tran-Thang; E K Kruithof; F Bachmann
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.